key: cord-1042578-cpfzjm7u authors: Seltzer, S. title: Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection date: 2020-09-17 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.09.041 sha: 54a9ccc7da6b041db302d5a2e13a0ce57fd08aab doc_id: 1042578 cord_uid: cpfzjm7u Angiotensin converting enzyme 2 (ACE2) is the receptor of the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the 2019 coronavirus disease (COVID-19) pandemic. ACE2 has been shown to be down-regulated during coronaviral infection with implications for circulatory homeostasis. In COVID-19 infection, pulmonary vascular dysregulation has been observed resulting in ventilation perfusion mismatches in lung tissue, causing profound hypoxemia. Despite the loss of ACE2 and raised circulating vasoconstrictor angiotensin II (AngII), COVID-19 patients experience a vasodilative vasculopathy. In this article, we discuss the interplay between the immune system and pulmonary vasculature and how SARS-CoV-2-mediated ACE2 disruption and AngII may contribute to the novel vascular pathophysiology of COVID-19. pulmonary vasculature and how SARS-CoV-2-mediated ACE2 disruption and AngII may contribute to the novel vascular pathophysiology of COVID-19. Angiotensin converting enzyme II ACE2 is the receptor of the novel coronavirus, SARS-CoV-2, responsible for the COVID-19 pandemic (1). ACE2 is a carboxypeptidase that cleaves AngII into angiotensin-(1-7), countering the vasoconstrictive effect of the ACE-Ang II-AT1 receptor axis of the renin-angiotensin system (RAS), an essential process in maintaining circulatory homeostasis (2) . Ang II is a vasoconstrictive peptide catalyzed from the proteolytic cleavage of angiotensin I by ACE in the lung that increases blood pressure (3) In coronaviral disease, ACE2 has been shown to be downregulated in lung tissue which has pathophysiological implications for infected patients; ; though it has not been explicitly demonstrated for SARS-CoV-2, the mechanism of viral binding and internalization of ACE2 is similar to SARS-CoV and may even produce a more dramatic depletion given the increased affinity of SARS-CoV-2 spike protein for ACE2 (4) (5) (6) (7) . ACE2 is a well-characterized regulator of pulmonary vasodilation, postulated as a potential treatment for pulmonary hypertension (8 The clinical observation of pulmonary vasodilation in CARDS and the presence of significantly increased AngII in COVID-19 disease requires further investigation (9, 13) . A current theory explaining this phenomenon involves the loss of hypoxic pulmonary vasoconstriction (HPV) (9) . The effect of AngII on HPV has been controversial; despite its vasoconstrictive activity, AngII does not influence HPV (14) . Conversely, recombinant ACE2 has been shown to counter HPV, indicating that the enzyme's down-regulation in a hypoxic patient should cause further vasoconstriction (15) . Additionally, AngII is elevated in patients with pulmonary hypertension, J o u r n a l P r e -p r o o f which should, in theory, steer the pathophysiology of increased AngII signalling in COVID-19 towards a vasoconstrictive and pulmonary hypertensive phenotype (16) . Interestingly, the conversion of AngII to angiotensin-(1-7) may even be independent of ACE2 activity in mice, indicating that the effect of ACE2 down-regulation, AngII up-regulation and pulmonary vasodilation in COVID-19 may require investigating these proteins beyond their counterregulatory effects on vascular tone and even beyond vascular tissue (17) . While clinical data for COVID-19 are ever-increasing, one can extrapolate the immunovascular effects of ACE2 and AngII dysregulation from in vitro and in vivo data (Table 1 ). In cultured EAhy926 ECs, ACE2 expression down-regulates macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine with implications for the pathogenesis of COVID-19 (18) . Interestingly, AngII has been shown to increase MIF expression through AT1 signalling in ECs, and is known to be pro-inflammatory, inducing M1 macrophages, thus both the loss of ACE2 and the observed increase AngII may bolster cytokine expression and macrophage activity in COVID-19 infection (18) (19) (20) . Moreover, ACE2 knockout mouse models have demonstrated significantly higher levels of interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP1) and matrix metalloproteinases 2 and 9 (MMP2/9) and tumour necrosis factor alpha (TNFα) in ECs, which are only further exacerbated by atherosclerosis, which is a risk factor for COVID-19 morbidity (21, 22) . Loss of ACE2 has also been shown to upregulate pro-inflammatory, vasodilative bradykinin signalling through the bradykinin B1 receptor (BKB1R), which also implicates the des-Arg(9) bradykinin pathway in COVID-19 pulmonary vasodilation (23). ACE2 knockout ECs also demonstrated increased responsiveness to TNFα which leads to endothelial damage (21) . Another knockout study in bone marrow resulted in increased expression of the macrophage markers F4/80 as well as TNFα (24) . A SARS-CoV-2-mediated down-regulation of ACE2 in macrophages may produce a similar TNFα-mediated proinflammatory, vasodilatory effect, which is further exacerbated by both ACE2 disinhibition and AngII-mediated enhancement of vascular MIF and MCP-1 expression and TNFα reactivity. Interestingly, AngII, MIF and TNFα are involved in vascular dysregulation and macrophage nitric-oxide (NO) production, which implicates these molecules in CARDS pulmonary vasculopathy (18, (25) (26) (27) . ACE2 deficiency has also been shown to increase vascular smooth muscle reactivity to NO, and while TNFα overall supresses EC NO synthase (eNOS) activity, it remains an important inducer of NO production in Th1 responding macrophages. Moreover, vasodilatory shock (28) (29) (30) . This indicates that NO production in early COVID-19 disease by macrophages, combined with cytokine-mediated vascular injury potentiated by ACE2 downregulation, increased AngII signalling and viral EC lysis may contribute to COVID-19 pulmonary vasculopathy (Fig. 2) (31, 32) . This immunovascular model of COVID-19 pathogenesis may also partially explain the effectiveness of immunosuppressive dexamethasone in COVID-19 patients requiring respiratory support (33) . In the presented model, one cannot discuss the RAS system without addressing the effects of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in COVID-19. Due to elevated circulating AngII in COVID-19 one would assume that modulators of the RAS system Dexamethasone-NCT04381936), we call for further investigation into this phenomenon in hopes of increasing the understanding of COVID-19 and its pathophysiology. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Increased (21) Increased (21) n/a n/a Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Renin-angiotensinaldosterone system and COVID-19 infection Conversion of angiotensin I to angiotensin II. The American journal of medicine The pivotal link between ACE2 deficiency and SARS-CoV-2 infection A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats COVID-19 pneumonia: ARDS or not? Critical Care COVID-19 pneumonia: different respiratory treatments for different phenotypes? Management of COVID-19 Respiratory Distress Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney EFFECT OF β2-ADRENOCEPTOR ACTIVATION AND ANGIOTENSIN II ON TUMOUR NECROSIS FACTOR AND INTERLEUKIN 6 GENE TRANSCRIPTION IN THE RAT RENAL RESIDENT MACROPHAGE CELLS Genetic Ace2 Deficiency Accentuates Vascular Inflammation and Atherosclerosis in the ApoE Knockout Mouse Association of Coronavirus Disease With Myocardial Injury and Mortality Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPSinduced neutrophil infiltration Deficiency of ACE2 in Bone-Marrow-Derived Cells Increases Expression of TNF-α in Adipose Stromal Cells and Augments Glucose Intolerance in Obese C57BL/6 Mice Angiotensin II induces RAW264.7 macrophage polarization to the M1-type through the connexin 43/NF-κB pathway Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis Genetic Deletion of ACE2 Induces Vascular Dysfunction in C57BL/6 Mice: Role of Nitric Oxide Imbalance and Oxidative Stress Effects of nitric oxide in septic shock Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report Figures created with BioRender.com